Nolvadex-D Tamoxifen 20mg Breast Cancer & Hormonal Therapy Tablets 30s

• Tamoxifen citrate 20mg (equivalent to 30.4mg tamoxifen citrate) tablets • Selective estrogen receptor modulator (SERM) for breast cancer treatment • Reduces risk of recurrence in hormone-receptor-positive cases • Once- or twice-daily oral dosing • Suitable for adjuvant therapy, metastatic disease, and high-risk prevention • Film-coated tablets for improved tolerability • Requires long-term use (5–10 years) under oncologist supervision

Nolvadex-D 20mg Tablets contain tamoxifen, a non-steroidal anti-estrogen that competitively blocks estrogen receptors in breast tissue. Indicated for adjuvant treatment of early-stage ER+ breast cancer post-surgery, reduction of contralateral breast cancer risk, metastatic ER+ breast cancer, and ductal carcinoma in situ (DCIS) after lumpectomy/radiation. Also used in high-risk women to reduce primary breast cancer incidence. Regular monitoring of endometrium, liver function and eyes required. Benefits • Reduces recurrence risk by ~40–50% in ER+ patients • Lowers mortality in hormone-positive breast cancer • Once-daily regimen improves adherence • Proven in long-term studies (NSABP, ATLAS, IBIS-I) • Oral alternative to aromatase inhibitors in pre-menopausal women • May preserve bone density in postmenopausal women • Generic version offers cost-effective long-term therapy How to Use • Usual dose: 20mg once daily or 10mg twice daily • Swallow whole with water; with or without food • Take at same time each day • Continue for 5–10 years as prescribed (adjuvant) • Do not stop abruptly without oncologist advice • Missed dose: take as soon as remembered unless near next dose • Store below 30°C in original packaging